| abstract |
The invention relates to a drug for local use for the purpose of hemostasisnand / or wound closure and / or wound healing promotion, which are conventional as drugsnfrom allogeneic plasma or tissue or genetically engineered fibrinogennor fibrin, thrombin and one or more transglutaminases, whereinnthe drug contains as another active ingredient one or more protease inhibitors whichnfrom the group of serpins that have no inhibitory effect on collagenases and elastasesnpossess, are selected, whereby all active substances of allogenen origin and a procedurensubject to virus depletion and / or virus inactivation, with the proviso thatnvirus inactivation of the one or more protease inhibitors not in the presencenthe other active ingredients has been carried out. |